23:28 , Feb 13, 2019 |  BC Week In Review  |  Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
20:26 , Feb 11, 2019 |  BC Extra  |  Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
01:14 , Nov 16, 2018 |  BC Innovations  |  Emerging Company Profile

Virion: Harnessing viral defects

Virion Biotherapeutics Ltd. has capitalized on a naturally occurring viral mutation to develop broad-spectrum antivirals with lower potential for resistance than marketed products. Its lead compound, VH244, is in preclinical development to treat respiratory infections...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
22:15 , Sep 21, 2018 |  BC Extra  |  Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
22:35 , Sep 20, 2018 |  BC Extra  |  Company News

Management tracks: Garland to lead Portola; Gallagher joining Abingworth

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) hired Scott Garland as president and CEO. He replaces CEO Bill Lis, who retired Aug. 1. Interim Co-Presidents John Curnutte, the company’s head of R&D, and Mardi Dier, its...
22:10 , Sep 17, 2018 |  BC Extra  |  Company News

Management tracks: Ultragenyx, Epizyme

Rare and ultra-rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appointed Wladimir Hogenhuis as COO. Previously, he was SVP and general manager, specialty franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Epizyme Inc. (NASDAQ:EPZM) said CBO Susan Graf...